Eisai Co., Ltd. (4523.T)

6.632,00 +143,00 (+2,20%) Alla chiusura: 03:00PM JST

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 11.067

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Haruo Naito	CEO, Representative Corporate Officer & Director	N/D	N/D	1947
Mr. Gary Hendler	Senior VP & President of EMEA Region	N/D	N/D	1966
Dr. Lynn D. Kramer FAAN, M.D.	Vice President & Chief Clinical Officer - Alzheimer's Disease and Brain Health	N/D	N/D	1950
Ms. Yanhui Feng	Senior Vice President	N/D	N/D	1972
Dr. Nadeem Sarwar Ph.D.	President	N/D	N/D	N/D
Mitsuru Shomon	VP & CFO	N/D	N/D	N/D
Mr. Yasushi Okada	Representative Corporate Officer, COO, Industry Affairs, China Business & Data Integrity	N/D	N/D	1958
Makoto Hoketsu	VP & Chief Information Officer	N/D	N/D	N/D
Mr. Masatomi Akana	Chief Gov. Rel. and IR Officer, SVP of Global Value, Acc., Japan Subs, General, Env. & Safety Aff.	N/D	N/D	1967
Mr. Kenta Takahashi	Executive VP of IP, Internal Audit & Control, General Counsel and Chief Compliance Officer	N/D	N/D	1959

Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in JPY.

Descrizione

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Governance aziendale

L'ISS Governance QualityScore di Eisai Co., Ltd. al 1 giugno 2024 è 1. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 1; diritti degli azionisti: 7; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.